An artificial intelligence method to assess the tumor microenvironment with treatment outcomes for gastric cancer patients after gastrectomy.
An artificial intelligence method to assess the tumor microenvironment with treatment outcomes for gastric cancer patients after gastrectomy.
复制标题
DOI：
10.1186/s12967-022-03298-7
复制
发表时间：
2022-02-21
影响因子：
7.4
通讯作者：
Li G
中科院分区：
文献类型：
--
作者：
Chen T;Li X;Mao Q;Wang Y;Li H;Wang C;Shen Y;Guo E;He Q;Tian J;Zhu M;Wu J;Liang W;Liu H;Yu J;Li G
肿瘤微环境（TME）在胃癌（GC）的发生、发展中起着重要作用，被广泛用于评价GC患者的治疗效果。免疫组织化学（IHC）和基因测序是TME的主要分析方法，但由于观察者的主观性，设备的高成本和对专业分析人员的需求而受到限制。在TCGA队列中开发了免疫评分（IS），并在GEO队列中进行了验证。放射组学免疫评分（RIS）在TCGA队列中开发，并在南方队列中验证。基于RIS和临床特征，在南方队列中开发并验证了诺模图。对于IS，2年总生存期（OS）的曲线下面积（AUC）为0.798，4年总生存期为0.873。对于RIS，在TCGA队列中，区分高IS或低IS和预测预后的AUC分别为0.85和0.81;在南方队列中，预测预后的AUC为0.72。根据ROC曲线，诺模图法优于TNM分期法（均P < 0.01）。高列线图组中TNM分期为II期和III期的患者比低列线图组患者更可能从辅助化疗中获益。RIS和列线图可用于评估胃癌根治术后的TME、预后和辅助化疗获益，是对现有TNM分期系统的有价值的补充。高列线图的胃癌患者可能比低列线图的胃癌患者从辅助化疗中获益更多。在线版本包含补充材料，可通过10.1186/s12967-022-03298-7获得。
The tumor microenvironment (TME) plays an important role in the occurrence and development of gastric cancer (GC) and is widely used to assess the treatment outcomes of GC patients. Immunohistochemistry (IHC) and gene sequencing are the main analysis methods for the TME but are limited due to the subjectivity of observers, the high cost of equipment and the need for professional analysts. The ImmunoScore (IS) was developed in the TCGA cohort and validated in GEO cohorts. The Radiomic ImmunoScore (RIS) was developed in the TCGA cohort and validated in the Nanfang cohort. A nomogram was developed and validated in the Nanfang cohort based on RIS and clinical features. For IS, the area under the curves (AUCs) were 0.798 for 2-year overall survival (OS) and 0.873 for 4-year overall survival. For RIS, in the TCGA cohort, the AUCs distinguishing High-IS or Low-IS and predicting prognosis were 0.85 and 0.81, respectively; in the Nanfang cohort, the AUC predicting prognosis was 0.72. The nomogram performed better than the TNM staging system according to the ROC curve (all P < 0.01). Patients with TNM stage II and III in the High-nomogram group were more likely to benefit from adjuvant chemotherapy than Low-nomogram group patients. The RIS and the nomogram can be used to assess the TME, prognosis and adjuvant chemotherapy benefit of GC patients after radical gastrectomy and are valuable additions to the current TNM staging system. High-nomogram GC patients may benefit more from adjuvant chemotherapy than Low-nomogram GC patients. The online version contains supplementary material available at 10.1186/s12967-022-03298-7.
登录
查看更多内容
影响因子：
6
作者：
Bockamp E;Rosigkeit S;Siegl D;Schuppan D
通讯作者：
Schuppan D
影响因子：
4.3
作者：
Lazăr DC;Avram MF;Romoșan I;Cornianu M;Tăban S;Goldiș A
通讯作者：
Goldiș A
影响因子：
45.3
作者：
Lynch, Thomas J.;Bondarenko, Igor;Reck, Martin
通讯作者：
Reck, Martin
DOI：
10.3760/cma.j.issn.0253-3766.2018.11.001
发表时间：
2018-11-23
期刊：
Zhonghua zhong liu za zhi [Chinese journal of oncology]
影响因子：
--
作者：
Li, Q;Ye, Z X
通讯作者：
Ye, Z X
影响因子：
78.8
作者：
Bera, Kaustav;Schalper, Kurt A.;Madabhushi, Anant
通讯作者：
Madabhushi, Anant